Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy

Journal of Crohn's and Colitis

Volumn 7, Issue 5, 2013, Pages 412-418

  Greveson, Kay ^a   Goodhand, James ^a   Capocci, Santino ^a   Woodward, Sue ^b   Murray, Charles ^a   Cropley, Ian ^a   Hamilton, Mark ^a   Lipman, Marc ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Inflammatory bowel disease; Interferon gamma release assay; Screening; Tuberculosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BCG VACCINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; ENTERITIS; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THORAX RADIOGRAPHY; TUBERCULIN TEST; ULCERATIVE COLITIS; UNITED KINGDOM; VACCINATION;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875576458     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.08.010     Document Type: Article

References (22)

1. Solovic I., Sester M., Gomez-Reino J. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010, 36:1185-1206.
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2005, 359:1541-1549.
3. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomised controlled trials. JAMA 2006, 295:2275-2285.
4. National Institute for Health and Clinical Excellence. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011 (Accessed 29th February 2012). http://guidance.nice.org.uk/CG117/Guidance/pdf/English.
5. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
6. British Thoracic society BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNFα treatment. Thorax 2005, 60:800-805.
7. Centers for disease control, prevention Interferon-gamma release assays (IGRAs)- blood tests for TB infection (Fact sheet) (accessed 1st February 2012). http://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf.
8. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3(2):47-91.
9. Pooran A., Booth H., Miller R., Scott G., Motasim B., Huggett J., et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010, 10:7.
10. NRES Differentiating audit, service evaluation and research (accessed 1st February 2012). http://www.nres.npsa.nhs.uk/applications/guidance.
11. Vassilopoulos D., Stamoulis N., Hadziyannis E., Archimandritis A.J. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol. 2008, 35(7):1464.
12. Ferrara G., Losi M., D'Amico R. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006, 367(9519):1328-1334.
13. Piana F., Codecasa L.R., Cavallerio P., Ferrarese M., Migliori G.B., Barbarano L., et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006, 28:31-34.
14. Wrighton-Smith P., Zelwegger J.P. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006, 28:45-50.
15. Diel R., Nienhaus A., Lange C., et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006, 28:1285.
16. Greveson K., Murray C., Toumpanakis C., Epstein O., Hamilton M., Lipman M. Interferon gamma-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFα therapy. Frontline Gastroenterol 2010, 2:26-31.
17. Schoepfer A.M., Flogerzi B., Fallegger S., Schaffer T., Mueller S., Nicod L., et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008, 103:2799-2806.
18. Richeldi L., Losi M., Cerri S., Casali L., Fabbri L.M., Ferrara G. Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay. Expert Rev Respir Med 2008, 2:253-260.
19. Diel R., Loddenkemper R., Neinhaus A. Evidence-based comparison of commercial interferon gamma release assays for detecting active Tb: a meta-analysis. Chest 2010, 137:952-968.
20. Papay P., Eser A., Winkler S., Frantal S., Primas C., Miehsler W., et al. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest Oct 2011, 41(10):1071-1076. [Epub 2011 Mar 17]. 10.1111/j.1365-2362.2011.02502.x.
21. Papay P., Eser A., Winkler S., Frantal S., Primas C., Miehsler W., et al. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17:84-90.
22. Pai M., Riley L.W., Colford J.M. Interferon gamma release assays in the immunodiagnosis of tuberculosis; a systematic review. Lancet Infect Dis 2004, 4:761-776.